Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Drug Discovery Platform
Pharmaceutical Research Platform
Preclinical Research Services
Botanical Drug Preclinical R&D Technology Platform
02 Innovative Drug Services
ADC R&D Service Platform
PROTAC R&D Service Platform
mRNA Vaccine Bioanalysis Platform
Non-clinical Research for Cellular Immunotherapies
Nucleic Acid Drug R&D Platform
Peptide Drug Conjugate (PDC) R&D Service Platform
Antibody R&D Service
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Platform
Metabolite Identification (MetID) Service Platform
Drug Forming Research Platform
Flow Cytometry Technology Platform
SEND Format Conversion Platform
Flow Sorting Platform
NanoString nCounter Detection Platform
Routes of Drug Administration Platform
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model Evaluation Platform
Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease Drug Efficacy Evaluation System
05 Advanced Preparation R&D
Inhalation drug R&D platform
Ophthalmic drug R&D platform
Skin Topical Preparation R&D Platform
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Recruitment
Talent Development
Talent Development
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Jun 30,2021
[Medicilon Assist]KBMAB-16 for the Treatment of Sarcoidosis has been Approved by the FDA for Clinical Trials
Recently, the orphan drug KBMAB-16 (intravenous injection of tumor necrosis factor-α inhibitor), a major project of a well-known Chinese pharmaceutical company located in Chengdu, was successfully approved for clinical trial application (IND) by the US Food and Drug Administration (US FDA).
More
[Medicilon Assist]KBMAB-16 for the Treatment of Sarcoidosis has been Approved by the FDA for Clinical Trials
Jun 25,2021
Medicilon's "New Drugs + AI Innov Forum" was successful held
When AI accurately predicts the "difficult” protein 3D structure; When AI completes the new drug design within 21 days; When AI discovers a new mechanism
More
Medicilon's "New Drugs + AI Innov Forum" was successful held
Jun 08,2021
Medicilon assists Palaatu to obtain clinical approval for Class 1 new drug PA9159 for rhinitis
On June 2, 2021, the National Medical Products Administration (NMPA) officially announced that the glucocorticoid drug PA9159 nasal spray was approved for clinical use.
More
Medicilon assists Palaatu to obtain clinical approval for Class 1 new drug PA9159 for rhinitis
May 14,2021
Safety assessment lab of process chemistry
Safety assessment lab of process chemistry In the research and development process of innovative drugs, the chemical process research of drugs plays a pivotal role. 
More
Safety assessment lab of process chemistry
May 01,2021
Vastpro and Medicilon signed a strategic cooperation agreement for pre-clinical IND application services
On July 15, 2021, Vastpro and Medicilon signed a strategic cooperation agreement in the Medicilon Chuansha Park to reach a long-term strategic cooperation relationship.Vastpro president
More
Vastpro and Medicilon signed a strategic cooperation agreement for pre-clinical IND application services
Apr 25,2021
Medicilon Appoints Two Vice Presidents
Shanghai Medicilon Inc. recently assigned Dr. Haifeng Yin as the vice president of process chemistry and formulation study, Dr. Baohong Cao as the vice president
More
Medicilon Appoints Two Vice Presidents
Apr 21,2021
Medicilon assists HitGen's HG381 to be approved as China's first clinical STING agonist
On April 8, 2021, the clinical trial application of HG381 for injection, developed by HitGen, was approved by National Medical Products Administration (NMPA).  HG381 for
More
Medicilon assists HitGen's HG381 to be approved as China's first clinical STING agonist
Apr 08,2021
Medicilon will participate 2021 AACR Virtual Annual Meeting
#Medicilon will exhibit the 2021 AACR Virtual Annual Meeting from April 10-15.  Please visit our virtual booth for more information on our oncology and preclinical
More
Medicilon will participate 2021 AACR Virtual Annual Meeting
Mar 29,2021
Medicilon assists Livzon Pharmaceuticals Group to obtain the clinical approval of novel coronavirus vaccine V-01
Livzon Pharmaceutical Group Inc. (Livzon) obtained a "novel coronavirus recombinant protein vaccine” (V-01) clinical trial approval from the National Medical Products Administration (NMPA) (Batch No.
More
Medicilon assists Livzon Pharmaceuticals Group to obtain the clinical approval of novel coronavirus vaccine V-01
Mar 08,2021
Medicilon will participate 2021 SOT Virtual Annual Meeting
Medicilon will exhibit the 2021 SOT Virtual Annual Meeting from March 12-26.  Please visit our virtual booth to meet our VPs, Dr. Frank Wang, Dr.
More
Medicilon will participate 2021 SOT Virtual Annual Meeting
Feb 25,2021
Medicilon assists TransThera to obtain the Chinese IND for the VAP-1 inhibitor TT-01025, which has the first human subject in the USA
On February 22, 2021, Nanjing TransThera Biosciences Co., Ltd. ("TransThera”) and the life science company of South Korea's LG Chem ("LG Chem”) jointly announced the
More
Medicilon assists TransThera to obtain the Chinese IND for the VAP-1 inhibitor TT-01025, which has the first human subject in the USA
Feb 10,2021
Happy Chinese New Year
Thank you for your business, support and partnership in 2020!  Medicilon appreciates working with you and hope that the coming year will bring you happiness
More
Happy Chinese New Year
Stock Code
688202

Global

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->